Efficacy

Efficacy results (Table 2) were confirmatory and supportive of those from ARG-911. There were significant improvements in the composite endpoint for argatroban-treated patients versus controls among those with HIT (28.0% vs. 38.8%, p = 0.04) or HITTS (41.5% vs. 56.5%, p = 0.07). Argatroban treatment was significantly favored, compared with control, by time-to-event analysis of the composite endpoint in HIT (p = 0.02, hazard ratio = 0.64, 95% CI, 0.43-0.93) or HITTS (p = 0.008, hazard ratio = 0.56, 95% CI, 0.36-0.87).

TABLE 2 Comparisons of Argatroban-Treated Patients and Historical Controls with Acute HIT in Argatroban-915

TABLE 2 Comparisons of Argatroban-Treated Patients and Historical Controls with Acute HIT in Argatroban-915

0 0

Post a comment